Aurion Biotech logo

Aurion Biotech

aurionbiotech.com

Aurion Biotech develops regenerative cell therapies for the treatment of blindness and vision loss, with a lead program focused on corneal endothelial cell therapy for patients with corneal endothelial disease. Its therapies aim to restore vision by replacing lost or dysfunctional endothelial cells using human donor cells, providing a less invasive alternative to traditional corneal transplantation. The organization’s mission is to expand global access to advanced ophthalmic care and address significant unmet needs in treating blindness.

Facts

HQ
Seattle
Sectors
Biotechnology
Founded
2022
Employees
116
Stage
Clinical stage
Members see funding amounts.
.

Is this your organization? Claim it

Gennev Founder Jill Angelo Steps Down After Acquisition; Aurion Biotech CEO Replaced Following Alcon Majority Stake; Temporal Adds New Leadership

Jill Angelo, founder and CEO of menopause startup Gennev, stepped down following its acquisition by Unified Women’s Healthcare, while Aurion Biotech replaced CEO Greg Kunst with Arnaud Lacoste after Alcon acquired a majority stake. Temporal also announced leadership additions with Jim Cyb as president and Sahir Azam as an independent board member.

See all 6 stories, episodes and videos about Aurion Biotech.

People

  • Arnaud Lacoste Executive, Executive Officer, CEO and Chief Scientific Officer
  • Greg Kunst Executive, Executive Officer, Director, CEO

Online